Stock comparison

PFEvsRPRX

Pfizer IncvsRoyalty Pharma PLC. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

PFE

Pfizer Inc

$26.67

+3.17%

Pharmaceuticals$155.1BNYSE

RPRX

Royalty Pharma PLC

$49.3

+27.03%

Pharmaceuticals$27.1BNASDAQ

60-day price, rebased to 100

PFE +3.13% · RPRX +21.01%

Round-by-round

PFE 3·RPRX 2· 1tie

EdgePFE

Valuation upside

-18.10% vs -57.20% to DCF fair value

Tie

Balance-sheet strength

Altman Z 2.15 vs 2.25

EdgePFE

Fundamental quality

Piotroski 6.00 vs 5.00 (of 9)

EdgeRPRX

Growth + margins

Rule-of-40 12.90 vs 109.80

EdgeRPRX

60-day momentum

+3.13% vs +21.01% price return

EdgePFE

Market-cap liquidity

$155.1B vs $27.1B

Verdict

Across6categories,PFEtakes the edge with3wins to2 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onPFEorRPRX

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.